MorphoSys Terminates Merger Talks

genomeweb
360dx

MorphoSys Terminates Merger Talks

Oct 23, 2002

NEW YORK, Oct. 23-The German synthetic antibody firm MorphoSys said today that it had terminated merger talks with British Biotech, a publicly owned drug development company.

To read the full story....

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

Noridian Issues Draft LCD for GenomeDx Prostate Biopsy Genomic Classifier
Predicine, Flagship Biosciences to Provide Combined Service
Study Monitors Exposure of Individuals to Airborne Biologics, Chemicals
Genomics Medicine Ireland, Academic Collaborators to Study Asthma Genetics
European Cancer Charities Award $39.4M in Research Grants
Drugs Targeting Lipolysis Could Confer Additional Cardiovascular Benefit, Genetic Analysis Finds

The Scan

From Tusk to Cartel

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

The Same Genes Keep Getting Asked to Prom

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

Keep Them in the Know

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

This Week in Nature

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.

Main menu